kbpa-101
mAbexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2008 (NCT00851435)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Lipopolysaccharide (LPS)INHIBITOR
Lipopolysaccharide (LPS) inhibitor
- PseudomonasImmunity, passive
Pseudomonas immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109535 ↗
Also known as
- kbpa-101
- kbpa-101
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00851435 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2008 | Kenta Biotech Ltd |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kenta Biotech Ltd | For profit | 1 | 1 | 1 | 2008 |
1 organizations
Page 1 / 1